
In one of Friday’s opening sessions of PMWC 2025, Collen Masimirembwa, PhD, PHARMD, Founder, President, and CSO of the African Institute of Biomedical Science & Technology in Harare, Zimbabwe, was awarded a PMWC Pioneer Award for his contributions to pharmacogenomics in understanding genetic factors affecting drug response in diverse populations. After accepting his prestigious award, Masimirembwa delivered a presentation entitled “Genomic Diversity in Africa: Pharmacogenetics and Clinical Implications.” He is also a Distinguished Professor at the Sydney Brenner Institute for Molecular Biosciences, University of the Witwatersrand, Johannesburg, South Africa. Masimirembwa is a champion of pharmacogenomics research in Africa. Born in Zimbabwe, he studied at the University of Zimbabwe and the Karolinska Institute in Sweden, where he focused on drug metabolism and pharmacokinetics. He worked at AstraZeneca in Sweden before founding the African Institute of Biomedical Science and Technology in Zimbabwe. His achievements include establishing the African Pharmacogenomics Research Network under which he is conducting the first multinational study on the implementation of pharmacogenomics guided treatment in Africa. His work, which includes over 130 peer-reviewed papers, focuses on understanding the genomic diversity of African populations which is significantly impacting global health, particularly in enhancing drug efficacy and safety. His contributions have earned him the Bill & Melinda Gates Foundation Calestous Juma Science Leadership and the African Academy of Sciences fellowships, along with multiple prestigious awards. He made quite a travel effort to attend this year’s PMWC meeting and mentioned to BioQuick News that he was not looking forward to the long trip home which would take over 20 air-borne hours in moving from San Francisco to Dubai and then on to Zimbabwe.
In another of the final day’s opening sessions, Kari Stefansson, MD, CEO, deCODE Genetics in Iceland, was recognized with a PMWC Pioneer Award for his landmark work at deCODE that has significantly advanced the understanding of the genetic basis of human diseases and the role of genetic variation in health and disease. His keynote presentation, titled “Human Diversity—Connecting Blood Proteomics, Genomics, and Environment,” focused on how human diversity begins in the diversity of the sequences of nucleotides in the genome but the environment and interactions between the environment and the sequence contribute significantly. He discussed how blood proteomics in the context of sequence of the genome allows us to capture environmental impact on human diversity. Stefansson is recognized as a leading figure in human genetics. He has shaped deCODE’s scientific approach and been actively engaged in leading its gene discovery work, serving as senior author on most of the company’s publications in major scientific journals. In addition to his morning presentation, Stefansson engaged in a lively Q&A with Cindy Lawley, PhD, Director of Population Health at Olink Proteomics, in the last session of the three-day conference.
Federated Data Platforms
In an early afternoon presentation attended by BioQuick News, Noah Nasser, CEO, datma, spoke on“Empowering AI in Precision Medicine with Federated Dated Platforms.” datma.FEDis a secure, compliant federated platform for real-world data that bridges the gap between data custodians (in-house health system labs, reference labs) and data consumers (the pharmaceutical industry), fostering a symbiotic relationship. It allows organizations to turn their underutilized lab data into consistent revenue and drive innovation.
Nasser is a healthcare executive with over 30 years of experience in biotechnology, genomics, and molecular diagnostics. He is leading efforts to revolutionize healthcare through innovative data solutions, including the launch of a federated real-world data marketplace that enables secure, scalable collaboration and data sharing between custodians and consumers. Previously, Nasser was CEO of Serimmune, where he led the company through multiple funding rounds and launched its immuno-mapping technology. He has held senior leadership roles at Human Longevity, Inc., Counsyl, AltheaDx, Verinata Health, and Quidel Corporation, driving commercialization and business growth. Known for his ability to innovate and scale businesses, Nasser is positioned to shape the future of healthcare data. He is also an Executive in Residence at the University of Utah’s Center for Technology and Commercialization.
Panel Discussions
The morning included multiple panel discussions. The first was titled “Harnessing Emerging Diagnostic Technologies in Primary and Clinical Care.” Chair of the panel was Mylynda B. Massart, MD, PhD, Family Medicine Physician, University of Pittsburgh Medical Center; she is also the Founder and Medical Director at the UPMC Primary Care Precision Medicine Center integrating genomics into primary care. Panelists included Christopher Woods, MD, Wolfgang Joklik Distinguished Professor of Global Health, Duke; Yvonne Maldonado, MD, Professor of Pediatrics and of Health Research and Policy, Stanford; and Rose Lee, MD, MPH, Microbiology Director, NIH.
A second panel discussion was chaired by Charles Chiu, MD, PhD, Professor at UCSF, Director of the UCS-FAbbott Viral Diagnostics and Discovery Center (VDDC), and Associate Director of the UCSF Clinical Microbiology Laboratory. The discussion was titled “New Viral and Microbiome Associations with Cancer.” Panelists included Melody Smith, MD,Assistant Professor of Medicine, Stanford, and Nancy M. Joseph, MD, PhD, Professor of Pathology, UCSF.
A third panel, titled “Advancements in Clinical Genomics,” was chaired by Sivan Bercovici, PhD, Chief Technology and Business Officer, Karius; and included Charles Chiu; Robert Schloberg, MD, MPH, Distinguished Scientist, Infectious Disease, and VP, Illumina; and Catherine Hogan, MD, Medical Microbiologist, the British Columbia Centre for Disease Control, University of British Columbia.
10x Genomics
An early afternoon session featured Ben Hindson, PhD, CSO, Co-Founder, and President of 10x Genomics, who spoke on “Harnessing Single-Cell Genomics for Precision Disease Intervention.” Hindson noted that single-cell and spatial technologies are impacting nearly every aspect of biology and he presented on 10x Genomics’ latest advances on all three of the company’s major product platforms: Chromium, Visium, and Xenium. He described 10x efforts to enable more biology, expand the sets of samples and experiments that can be performed, and increase scale.
Award Winners
Friday’s session included the presentation of additional PMWC awards to notable scientists.
PMWC Pioneer Awards
The PMWC Pioneer Awards are given to venerable individuals whose foresight and ground-breaking contributions to precision medicine propelled the movement in earlier years, allowing it to gain momentum to evolve into the standard of care that it is becoming today.
Julie Louis Gerberding, MD, MPH, Foundation for the National Institutes of Health (FNIH), was awarded for pioneering precision medicine at the CDC, Merck, and FNIH.
Collen Masimirembwa, PhD, PHARMD, African Institute of Biomedical Science & Technology, was recognized for his contributions to pharmacogenomics, in understanding genetic factors affecting drug response in diverse populations.
Michael Snyder, PhD, Stanford, was recognized for his transformative work in genomics and wearable biosensors, catalyzing a shift towards predictive medicine.
Kari Stefansson, MD, deCODE Genetics, was awarded for his pioneering work at deCODE Genetics that has significantly advanced the understanding of the genetic basis of human diseases and the role of genetic variation in health and disease.
PMWC Luminary Awards
The PMWC Luminary Awards recognize the recent contributions of prominent figures who have accelerated precision medicine into the clinic.
Charles Chiu, MD, PhD, UCSF, was recognized for pioneering metagenomic sequencing technologies, revolutionizing infectious disease diagnostics with faster, more accurate detection, advancing patient care.
Philip Empey, PhD, PHARMD, University of Pittsburgh, was awarded for his contributions to the advancement and practical application of pharmacogenomics in clinical settings.
Jensen Huang, MSEE, Nvidia, was recognized for being an AI/HPC champion for next-generation precision medicine. He founded Nvidia in 1993 and has served since its inception as president, chief executive officer, and a member of the board of directors. Huang’s post-award address was perhaps the most attended session of the entire meeting as the audience was packed and standing-room-only.
PMWC 2025
This year’s PMWC is the largest ever with over 2,500 attendees, 400+ speakers, and 90+ exhibitors. It is a premier event for discussion of the latest advancements in the fast-moving field of precision medicine aimed at developing the optimal treatment for the right person at the right time. The conference ran from Wednesday, February 5, through Friday, February 7, in Santa Clara, California in the heart of Silicon Valley.
The attendees can be characterized as follows: 55% have PhDs and 30% have MDs; their positions include 44% top executive/director, 19% research scientist/PI, 15% physician/clinician, 9% lab head, 6% sales/marketing, 5% investor/investment banker, 2% patients; their organizations range from 30% pharma/biotech, 15% academia/research, 15% tools company/consumer, 10% medical centers, 10% health providers, to 5% media, 5% regulatory and reimbursement, 5% VC/finance, 3% miscellaneous, and 2% patients; and with respect to location, 45% come from the West Coast USA, 15% East Coast USA, 15% Midwest USA, 10% Europe, 10% Asia, and 5% from the rest of the world.
The world-class meeting is organized by Tal Behar, Founder and President of PMWC. The first meeting was held in 2009 and has grown steadily since. The co-hosts of this year’s and past meetings include UCSF, University of Michigan, Duke University, University of Pittsburgh, and Stanford Health Care/Stanford Medicine.
by Michael D. O’Neill, Editor & Publisher, BioQuick News, logophile2000@yahoo.com
